SHTDY (Sinopharm Group Co) Margin of Safety % (DCF FCF Based) : 84.48% (As of Apr. 06, 2025)

View and export this data going back to 2012. Start your Free Trial

What is Sinopharm Group Co Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2025-04-06), Sinopharm Group Co's Predictability Rank is 4.5-Stars. Sinopharm Group Co's intrinsic value calculated from the Discounted FCF model is $47.93 and current share price is $11.305. Consequently,

Sinopharm Group Co's Margin of Safety % (DCF FCF Based) using Discounted FCF model is 84.48%.

Competitive Comparison of Sinopharm Group Co's Margin of Safety % (DCF FCF Based)

For the Medical Distribution subindustry, Sinopharm Group Co's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinopharm Group Co's Margin of Safety % (DCF FCF Based) Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's Margin of Safety % (DCF FCF Based) falls into.

Save Embed

;

Save Embed

;

Sinopharm Group Co Margin of Safety % (DCF FCF Based) Calculation

Sinopharm Group Co's Margin of Safety % (DCF FCF Based) for today is calculated as

Margin of Safety % (DCF FCF Based)	=	(Intrinsic Value: DCF (FCF Based)	-	Current Price)	/	Intrinsic Value: DCF (FCF Based)
	=	(72.83	-	11.305)	/	72.83
	=	84.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted FCF model with default parameters. The calculation method is the same as Discounted Earnings model except free cash flow are used in the calculation instead of earnings per share.

Sinopharm Group Co Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDY) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

SHTDF:USA 01099:Hong Kong X2S:Germany

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Sinopharm Group Co Headlines

From GuruFocus

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon • 05-19-2016

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon • 10-18-2014

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan • 10-20-2014

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon • 05-19-2016

Arnold Van Den Berg Buys Prem Watsa's Fairfax India, 3 Other Stocks in 3rd Quarter

By Holly LaFon Holly LaFon • 10-31-2017

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood • 01-25-2021

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood • 07-30-2020

Sinopharm Group Co Ltd's Dividend Analysis

By GuruFocus Research • 06-17-2024